Comparative Pharmacology
Head-to-head clinical analysis: ALLOPURINOL versus DUZALLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLOPURINOL versus DUZALLO.
ALLOPURINOL vs DUZALLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Allopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Clinical Note
moderateAllopurinol + Hydrochlorothiazide
"The risk of a hypersensitivity reaction to Hydrochlorothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Bendroflumethiazide
"The risk of a hypersensitivity reaction to Bendroflumethiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Methyclothiazide
"The risk of a hypersensitivity reaction to Methyclothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateTerminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Allopurinol + Hydroflumethiazide
"The risk of a hypersensitivity reaction to Hydroflumethiazide is increased when it is combined with Allopurinol."